In this interview from EAN 2025, Prof. Michael Schöll discusses the evolving role of plasma biomarkers in Alzheimer’s diagnosis and treatment, the challenges of clinical implementation, and the innovations he believes will transform care pathways. Prof. Michael Schöll is Professor of Molecular Medicine at the University of Gothenburg, Sweden, and Principal Research Fellow at University College London (UCL), based at the renowned Queen Square Institute of Neurology. His research focuses on molecular imaging, fluid biomarkers, and early diagnostics for neurodegenerative diseases, particularly Alzheimer’s disease. Check out the full discussion, here:
